ArticleMedical devices (Auckland, N.Z.)2025
Hemostatic Benefits of an Absorbable Polysaccharide Powder in Redo Cardiac Surgery: A Comparative Study.
Article in Medical devices (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Redo cardiac surgery outcomes, including increased transfusions and risk of reoperation, worsen with post-operative bleeding. This study aimed to directly compare the use of an absorbable polysaccharide powder to no hemostatic agent use during planned non-emergent redo cardiac surgery. Methods: Fifty-one participants in two cohorts underwent planned non-emergent redo cardiac surgery. The retrospective cohort (n = 26) was chosen from redo cardiac surgeries completed between 2019 and 2020, while the prospective cohort (n = 25) included sequential redo cardiac surgeries with the use of an absorbable polysaccharide powder. Patient operative characteristics, along with first 24-hour transfusion use (packed red blood cells (pRBC), fresh frozen plasma (FFP) and platelets (Plts), chest tube outputs (CTO) at 12, 24 and 48 hours, and reoperation rates were compared. Results: There was a higher non-statistical average of intraoperative pRBC and FFP rates in the retrospective cohort, compared to cases where absorbable polysaccharide powder was used (2 ± 2.9 vs 1.1 ± 1.4 units pRBC, p = 0.414; and 1.4 ± 1.8 vs 0.6 ± 1 units FFP, p = 0.070) while there were statistical differences in Plts use in the retrospective cohort compared to when absorbable polysaccharide powder was used (1 ± 1.3 vs 0.4 ± 0.7 units plts, p = 0.028). Statistically significant lower amounts of CTO in the first 12 hours and the 12-24-hour intervals were found when absorbable polysaccharide powder was used (817 ± 520 vs 558 ± 352 milliliters, p = 0.028; and 1144 ± 704 vs 830 ± 474 milliliters, p = 0.044, respectively). There were three reoperations in the retrospective cohort due to suspected bleeding, compared to no reoperations in the absorbable polysaccharide powder cohort. Conclusion: This study highlights fewer transfusions, lower CTO, and decreased need for reoperation when using absorbable polysaccharide powder in redo cardiac surgeries. Further randomized trials are needed to more accurately define benefits of absorbable polysaccharide powder in redo cardiac surgeries. Word count: 302.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.